New York, January 16, 2026, 14:57 EST — Regular session
Shares of BridgeBio Pharma Inc edged up 0.5% to $76.66 Friday afternoon, following the announcement of a $550 million convertible notes sale. The stock swung between $75.87 and $78.12, with roughly 5.9 million shares changing hands. 1
This financing matters because it reshapes BridgeBio’s balance sheet in one go, extending maturities and cutting cash interest just as the company ramps up spending on commercialization and development.
Convertible notes offer a well-known setup for equity holders. They’re debt instruments that can convert into shares down the line at a fixed price. This usually helps keep borrowing costs down but risks diluting shareholders if the stock climbs high enough to prompt conversion.
The company announced the notes come with a 0.75% interest rate and an initial conversion price near $110.58 per share, about 45% above the last sale price of $76.26 on Jan. 15. BridgeBio expects net proceeds around $538.4 million. Buyers have an option to snap up an extra $82.5 million in notes. The firm said it will use the funds to repurchase or repay some of its 2.50% convertible notes maturing in 2027, as well as for general corporate needs. 2
BridgeBio first revealed plans for the offering Wednesday, framing it as part of a broader debt management strategy. The company also flagged the possibility of pairing the financing with share buybacks depending on pricing. 3
BridgeBio, launched in 2015, focuses on developing treatments for genetic disorders. Its pipeline covers everything from early research to late-stage clinical trials, according to its investor relations page. 4
Its commercial drug Attruby (acoramidis) received FDA approval in November 2024 for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a serious heart condition that can cause failure and require hospitalization. 5
Traders will be keeping an eye on the typical convertible “flow” in the short term — where buyers frequently hedge by offloading stock — a factor that can cloud price movements despite seemingly investor-friendly terms.
But the risks are tangible. A weak stock performance can amplify concerns about dilution, and any delay in trimming near-term debts could mean BridgeBio ends up with more leverage than some investors anticipated from this refinancing.
The next obvious trigger is settlement: the company expects the sale of the notes to close January 21, pending routine conditions. Investors will then watch closely to see how much of the 2027 notes are redeemed after the deal wraps up. 6
